News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

The Challenge of Designing Clinical Trials for AIDS-Related Kaposi’s Sarcoma

Jun 1, 1998
Susan E. Krown, MD
OncologyONCOLOGY Vol 12 No 6
Volume 12
Issue 6

The need for an article such as the one by Little et al is a clear sign that progress is occurring in the treatment of AIDS-related Kaposi’s sarcoma (KS). Without such progress, there would be no urgent need to refine the tools currently used to evaluate the activity of KS treatment.

The need for an article such as the one by Little et al is a clear sign that progress is occurring in the treatment of AIDS-related Kaposi’s sarcoma (KS). Without such progress, there would be no urgent need to refine the tools currently used to evaluate the activity of KS treatment.

The good news is that agents active against KS have been identified and, in some cases, have weathered the FDA review and approval process. The even better news is that advances in our understanding of the events that lead to the development of KS, together with the discovery of agents with the potential to inhibit this process, offer the promise of even more effective, less toxic KS therapies for patients who are now surviving longer with HIV infection.

Although the options for KS therapy are greater now than they were a few years ago, and even better treatment options may soon become available, the bad news is that KS remains as difficult as ever to evaluate. Why should the assessment of a tumor that usually occurs in plain view of the examiner pose such a challenge? Should it require "rocket science" to detect and document the status of easily visible cutaneous tumors and the benefits associated with tumor regression?

Reproducible, Quantitative Lesion Assessment Remains Elusive

The problems involved in KS evaluation are multifactorial. First, as the authors discuss, KS lesions on the skin and in visceral organs often do not lend themselves to reproducible, quantitative assessments. In the case of skin lesions, consistent counting and characterization of large numbers of lesions is hard to achieve, even for those experienced in KS evaluation. The process is not only time-consuming but also subject to error, particularly when large numbers of lesions are clustered together.

Obtaining group consensus on lesion nodularity, as the authors suggest, may be ideal but is impractical in all but the most specialized clinical settings. Even photographs, while desirable, may fail to adequately capture important changes in lesion nodularity or color, and high-quality photographs are difficult, expensive, and time-consuming to obtain, especially in a busy clinic.

A ‘Disease Within A Disease’

Another, and perhaps more basic problem, is that KS in an HIV-infected individual is a "disease within a disease." Patients with tumors unrelated to HIV certainly may have comorbid conditions that influence their clinical course and the outcome of their cancer treatment. In patients with AIDS-associated KS, however, the outcome of KS therapy is linked in a fundamental way to the course of the underlying HIV infection.

For example, the development of an acute opportunistic infection during apparently successful therapy for KS may be associated with a sudden but temporary increase in KS lesions, quite possibly because of increased HIV activity and/or an abrupt surge in cytokine production. Should such progression be interpreted as "failure" of KS therapy, or as failure to control the underlying HIV infection?

Quality of life, analgesic require-ments, performance status, and other measures of patient "benefit" should certainly be part of the equation for evaluating new KS therapies. However, linking changes in symptoms and functional capacity specifically to the effects of KS therapy may be difficult in a multisystem disease such as AIDS.

Assessing the Value of KS Therapy

As Little et al conclude, recent experiences with FDA evaluation of new drugs for KS underscore the need to develop better quantitative methods to assess the value of KS therapy. Having attended several of the advisory committee meetings during which the value of these drugs was debated, I have been struck by two things in particular: The often moving, eloquent public statements made by patients whose lives had been positively affected by therapy for KS, and the very difficult and frustrating ordeal the investigators and pharmaceutical companies sometimes encountered in convincing the advisory panel that such benefits had occurred in more than these few self-selected, articulate individuals. Although the patients described reduced edema, improved function, decreased pain, enhanced self-esteem, and the ability to return to work after treatment, documentation of such improvements was not always collected uniformly or prospectively because standardized tools to gather this information had not been developed or validated.

Although "high-tech" methods, such as the one used at the National Cancer Institute (NCI) to measure changes in the volume of pulmonary KS lesions on computed tomographic (CT) scans or the use of sonograms to measure changes in the volume of cutaneous KS nodules,[1] could increase the precision of KS response assessment, quantitation of patient benefit is still decidedly "low-tech." In a 1989 editorial that accompanied the initial AIDS Clinical Trials Group (ACTG) recommendations for KS assessment and staging,[2] Volberding[3] stated that "before we agree on the ‘best’ agents . . . we must first develop a professional vocabulary that allows us to describe our patients and define the parameters used to compare clinical trials."

Although the ACTG criteria represented a step forward, in 1998, 17 years after the first description of AIDS-related KS, we are still struggling to refine the "vocabulary." The current joint effort by the NCI, FDA, and AIDS Malignancy Consortium (AMC) to introduce greater precision into KS response assessments and to correlate response with tangible clinical benefits, such as pain relief and improved function, is an important step in this direction.

Referral of Patients to Clinical Trials

The most comprehensive evaluation criteria will be of little value, however, if patients are not enrolled in clinical trials of promising new agents. Unfortunately, many patients with KS are not referred to oncologists until quite late in the course of their disease. I strongly endorse the idea that patients with limited, "early" KS (and also relatively early and/or optimally suppressed HIV infection) are ideal subjects in whom to test the feasibility of pathogenesis-based therapeutic strategies.

Although the establishment of the AMC and AIDS malignancy initiatives within the cancer cooperative groups should foster the development of better strategies for treating KS, as well as strategies to prevent the development of KS in high-risk individuals, it is essential that the support of primary HIV care providers, patients, and patient advocacy groups be enlisted. Convincing these groups that early referral and intervention may ultimately yield long-term benefits, and possibly obviate the need to use cytotoxic agents in many patients, should be an immediate priority. This will require more education of nononcologists about KS pathogenesis and its link to HIV infection.

References:

1. Bogner JR, Held M, Goebel FD: Cutaneous ultrasound for evaluation of Kaposi‘s sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 6:530-531, 1993.

2. Krown SE, Metroka C, Wernz JC: Kaposi’s sarcoma in the acquired immunodeficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 7:1201-1207, 1989.

3. Volberding PA: Moving toward a uniform staging for human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 7:1184-1185, 1989.

Articles in this issue

Radiofrequency Waves Used to Kill Inoperable Liver Tumors
ONS Receives Educational Grants to Fund Conferences
Genetic Markers May Predict Risk for Lung, Prostate, Colorectal, and Cervical Cancers
Salvage Therapy for Ovarian Cancer
Women’s Dissatisfaction With Body Image Can Affect Smoking
M. D. Anderson Initiates Aggressive Ovarian Cancer Screening Program
Application Deadline Draws Near for 1999 Charles E. Culpeper Foundation Scholarships in Medical Science
Gene May Provide Specific Target For Attacking Prostate Cancer
Medicare Now Reimburses Cancer Patients for Granisetron Tablets
Chemotherapy May Improve Quality of Life of Patients With Incurable Cancer
Emotional Support Groups Produce Mixed Results For Breast Cancer Patients
Common Mutations Linked to Increased Breast Cancer Risk
Enzyme Essential to Red Blood Cell Production and Regulation Isolated
Salvage Therapy for Ovarian Cancer
Local Excision for Rectal Cancer: An Uncertain Future
Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content

Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma

June 6th 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population

June 4th 2023

Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma

May 24th 2023

Continuous Doxorubicin Does Not Improve Efficacy in Soft Tissue Sarcoma

May 19th 2023

Trabectedin/Radiation Fails to Yield Robust Responses in Myxoid Liposarcoma

May 14th 2023

Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma

June 6th 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population

June 4th 2023

Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma

May 24th 2023

Continuous Doxorubicin Does Not Improve Efficacy in Soft Tissue Sarcoma

May 19th 2023

Trabectedin/Radiation Fails to Yield Robust Responses in Myxoid Liposarcoma

May 14th 2023

Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma

June 6th 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population

June 4th 2023

Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma

May 24th 2023

Continuous Doxorubicin Does Not Improve Efficacy in Soft Tissue Sarcoma

May 19th 2023

Trabectedin/Radiation Fails to Yield Robust Responses in Myxoid Liposarcoma

May 14th 2023
Related Content

Most adverse effects in a phase 2 trial related to doxorubicin appear to be expected in the treatment of patients with soft tissue sarcoma.

Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma

June 6th 2023
Article

Most adverse effects in a phase 2 trial related to doxorubicin appear to be expected in the treatment of patients with soft tissue sarcoma.


Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017
Podcast

In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.


Nirogacestat Yields Significant Pain Reduction Desmoid Tumor Population | Image Credit: © David A Litman - stock.adobe.com.

Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population

June 4th 2023
Article

Nirogacestat also appears to improve progression-free survival compared with placebo among those with desmoid tumors in the phase 3 DeFi trial.


Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma | Image Credit: © David A Litman - stock.adobe.com.

Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma

May 24th 2023
Article

Manufacturers plan to halt further development of milademetan for liposarcoma following the publication of topline results from the phase 3 MANTRA trial.


A post hoc analysis indicates continuous intravenous infusion of doxorubicin did not yield additional benefit for patients with soft-tissue sarcoma compared with bolus delivery methods.

Continuous Doxorubicin Does Not Improve Efficacy in Soft Tissue Sarcoma

May 19th 2023
Article

A post hoc analysis indicates continuous intravenous infusion of doxorubicin does not yield additional benefit for patients with soft-tissue sarcoma compared with bolus delivery methods.


Findings from a phase 2 trial suggest that trabectedin plus radiotherapy is a tolerable treatment option in patients with myxoid liposarcoma despite yielding an unsatisfactory overall response rate.

Trabectedin/Radiation Fails to Yield Robust Responses in Myxoid Liposarcoma

May 14th 2023
Article

Findings from a phase 2 trial suggest that trabectedin plus radiotherapy is a tolerable treatment option in patients with myxoid liposarcoma despite yielding an unsatisfactory overall response rate.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.